<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thiazolidinedione drugs are in widespread use for the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>In addition to improving insulin sensitivity, they generally result in a modest elevation of plasma <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>We report three patients, <z:hpo ids='HP_0000001'>all</z:hpo> of whom had preexisting diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, who showed a profound reduction in plasma <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> and <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> AI levels soon after the initiation of <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> therapy </plain></SENT>
<SENT sid="3" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> three patients, <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> levels returned to <z:mpath ids='MPATH_458'>normal</z:mpath> following <z:e sem="disease" ids="C0152128" disease_type="Disease or Syndrome" abbrv="">drug withdrawal</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The fact that this phenomenon was not seen in &gt;1,400 patients studied in clinical trials indicates that it is likely to be rare and idiosyncratic </plain></SENT>
<SENT sid="5" pm="."><plain>Until the frequency of this adverse reaction is clearer, it would seem advisable to ensure that plasma <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> is documented before and rechecked after commencement of thiazolidinedione therapy </plain></SENT>
</text></document>